Readout - Prime Minister Carney speaks with President of the European Commission Ursula von der Leyen
The leaders focused on how to make Canada and the European Union (EU) stronger and more competitive faced with changing trade relationships and economic uncertainty.
They discussed deepening their strategic partnership and boosting co-operation between Canada and the EU, as well as the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP).
They reviewed the success of the recent EU-Canada Summit and the progress made since then.
Canada and the EU are strengthening their partnership in key areas such as industrial policy, digital trade, critical raw materials, and clean technologies, in line with the commitments made at the Summit.
The leaders also talked about new opportunities to work together on defence industrial procurement and manufacturing, as part of their new Security and Defence Partnership.
Prime Minister Carney and President von der Leyen will stay in close contact and continue working closely together.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
FTase Inhibitor Market Set for Significant Growth Through 2034, Driven by Oncology and Rare Disease Applications
DelveInsight projects strong FTase inhibitors market growth through 2034, led by oncology and rare disease use. Key companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), Novartis (alpelisib combos), Eiger BioPharmaceuticals, and AnGes Inc. Advances target progeroid laminopathies, HRAS-mutant HNSCC, and novel indications, with approvals, partnerships, and late-stage trials driving expansion. DelveInsight's ' FTase Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 ' report delivers a comprehensive analysis of the FTase Inhibitor market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of FTase inhibitors in the 7MM is expected to surge significantly by 2034, driven by expanding applications in oncology and rare genetic disorders. Patient population data: The report provides the total FTase inhibitor potential pool, including Progeria cases occurring in approximately 1 in every 4 million live births worldwide and around 900K new head and neck squamous cell carcinoma cases each year. Key companies: Leading FTase inhibitor companies, such as Sentynl Therapeutics (formerly Eiger BioPharmaceuticals), Kura Oncology, and others are profiled. FTase Inhibitors Pipeline assets: Some of the key FTase inhibitor pipeline assets include tipifarnib in HRAS-mutant HNSCC and novel combination regimens with PI3Kα inhibitors. In March 2025, significant study published research on the highly active FTase peptide inhibitor PD083176 (d2,d3,d5) for treating acute liver failure (ALF), demonstrating that this optimized FTase inhibitor could attenuate ALF progression by modulating PANoptosis. Another research puslished in January 2025 demonstrated that lonafarnib (LNF), an approved oral FTase inhibitor, shows promise as an antiviral treatment against SARS-CoV-2. January 2024: ZOKINVY (lonafarnib) secured marketing approval in Japan via Eiger BioPharmaceuticals and partner AnGes Inc. May 2024: Sentynl Therapeutics closed the acquisition of the ZOKINVY program from Eiger BioPharmaceuticals. Discover recent advancements in the FTase Inhibitor landscape @ FTase Inhibitor Recent Developments. FTase Inhibitors Market Dynamics The FTase inhibitors market currently represents a niche yet high-growth segment within targeted therapeutics. As of 2025, the market remains modest in size, primarily anchored by ZOKINVY's orphan-disease indications, but is poised for expansion through oncology applications. FTase Inhibitors market momentum is propelled by validated survival benefits in ultra-rare progeroid laminopathies and emerging data in HRAS-driven cancers. Scientific rationale for FTase inhibition stems from the blockade of protein farnesylation, notably of progerin in HGPS and HRAS in HNSCC, disrupting aberrant cell signaling and proliferation. The FTase Inhibitors clinical development activity is robust, with tipifarnib advancing through Phase II/III trials both as monotherapy and in combination with Novartis's alpelisib. Additional early-stage candidates are exploring synergistic strategies to overcome resistance via dual prenylation pathway targeting. The FTase Inhibitor competitive landscape features established biotech players, with strategic alliances and licensing deals facilitating access to novel mechanisms and patient populations. For example, the Sentynl–AnGes partnership accelerated ZOKINVY's geographic reach, while Kura Oncology's collaborations underpin its oncology pipeline. FTase Inhibitors market barriers include compensatory prenylation pathways (geranylgeranylation) that may attenuate FTase inhibitor efficacy, and the ultra-orphan status limiting commercial scale. However, opportunities abound in biomarker-driven patient selection, combination regimens to deepen responses, and expansion into other RAS-dependent malignancies. Future outlook is characterized by anticipated label extensions, pipeline maturation, and reimbursement shifts as payers recognize the value of targeted disruption of oncogenic and progeroid pathways. Download the FTase Inhibitor Market report to understand which factors are driving the therapeutic market @ FTase Inhibitor Market Trends. FTase Inhibitors Targeted Patient Pool FTase inhibitors address indications such as progeroid laminopathies and head and neck squamous cell carcinoma. Epidemiology segmentation reveals that Hutchinson-Gilford Progeria Syndrome occurs in approximately 1 in 4 million live births, yielding around 400 affected children and young adults globally. Conversely, HNSCC accounts for roughly 890,000 new cases and 450,000 deaths annually worldwide. The total eligible patient pool for FTase inhibitors thus spans ultra-rare genetic disease patients and a subset of HRAS-mutant HNSCC. Real-world treated cases remain limited in progeria due to recent approvals, whereas oncology uptake is emerging in biomarker-enriched cohorts. Geographic segmentation shows the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan as primary markets, with forecasted growth over the 2020–2034 period driven by regulatory approvals, improved diagnostics, and expanded trial enrollment. Discover evolving trends in the FTase Inhibitor patient pool forecasts @ FTase Inhibitor Patient Pool Analysis. Key FTase Inhibitors Companies and Treatment Market The FTase inhibitors treatment landscape is anchored by ZOKINVY (lonafarnib), the first FDA-approved therapy for HGPS and processing-deficient progeroid laminopathies, now commercialized by Sentynl Therapeutics. Current treatment options for progeria are limited to lonafarnib, supplemented by supportive care measures. In oncology, no FTase inhibitor is yet approved, but tipifarnib (Kura Oncology) is in late-stage trials for HRAS-mutant HNSCC, both as monotherapy and in combination with alpelisib. Key FTase Inhibitors companies include Sentynl Therapeutics (ZOKINVY), Kura Oncology (tipifarnib), and strategic collaborators like Novartis (alpelisib combinations) and AnGes Inc. (Japan licensing). Market positioning for FTase inhibitors hinges on their unique mechanism of action, blocking prenylation to impair oncogenic signaling and progerin accumulation. Development milestones encompass ZOKINVY's 2020 FDA approval, its January 2024 Japanese approval, and its May 2024 acquisition by Sentynl. Kura Oncology's tipifarnib recently reported promising Phase II responses in HRAS-driven cohorts, earning Breakthrough Therapy Designation in select indications. Commercial arrangements include licensing of lonafarnib in Asia and co-development agreements for oncology combinations, underscoring the collaborative strategies propelling the FTase inhibitors market forward. Delve deeper into the major and specialised companies in the FTase Inhibitor market @ FTase Inhibitor Competitive Landscape. Conclusion The FTase inhibitors market is at an inflection point, transitioning from a rare-disease focus to broader oncology applications. With established clinical benefits, a robust pipeline, and strategic partnerships, FTase inhibitors are set to redefine treatment paradigms for progeroid disorders and HRAS-driven cancers through 2034 and beyond. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of FTase Inhibitor 4. Key Events 5. FTase Inhibitor Epidemiology Market Forecast Methodology 6. FTase Inhibitor Market Overview at a Glance in the 7MM 7. FTase Inhibitor: Background and Overview 8. Epidemiology and FTase Inhibitor Patient Population in Different Indications 9. FTase Inhibitor Target Patient Pool 10. FTase Inhibitor Marketed Therapies 11. FTase Inhibitor Emerging Therapies 12. FTase Inhibitor: Seven Major Market Analysis 13. FTase Inhibitor SWOT Analysis 14. KOL Views 15. FTase Inhibitor Unmet Needs 16. Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Cision Canada
41 minutes ago
- Cision Canada
CTERA Receives Frost & Sullivan's 2025 Global Company of the Year Award for Excellence in Hybrid Cloud Storage Leadership
Recognized for innovation and exceptional customer impact in the hybrid cloud storage market SAN ANTONIO, Aug. 13, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that CTERA has been awarded the 2025 Global Company of the Year Award in the Hybrid Cloud Storage market for the strength of its global file system platform, its industry-leading security capabilities, and its commitment to launching innovative product enhancements and creating a growth-oriented business. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: growth and innovation. CTERA excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. "CTERA's platform optimizes file storage and transfer in complex, multi-cloud environments. CTERA Direct, a service within the platform, enhances file transfer speeds via its ultra-fast, edge-to-cloud file transfer protocol, which provides fast movement of data for data-heavy workloads," said Karyn Price, Industry Principal, ICT, Frost & Sullivan. "Perhaps most compelling is the military-grade security capabilities that CTERA offers to its customers. The CTERA platform provides native data protection and restoration capabilities, enabling customers eliminate separate data protection services if they choose." Guided by a long-term growth strategy focused on hybrid cloud storage innovation, CTERA has shown its ability to adapt and lead in a rapidly evolving landscape. The company's strategic agility and sustained investment in its platform have enabled it to scale effectively across global markets and serve the demanding needs of both public and private sector clients. Innovation remains central to CTERA's approach. Its suite of data management solutions addresses the full spectrum of enterprise data challenges, offering seamless collaboration, high-speed data transfer, and unified data access across edge and cloud environments. "CTERA being recognized by Frost & Sullivan is truly an honor, reflecting our hard work and dedication. Our mission has always been to revolutionize cloud storage and data management, and this recognition motivates us to continue leading the way." CTERA's unwavering commitment to the customer experience further strengthens its position in the market. By streamlining service delivery, enabling self-service through advanced management portals, and maintaining high levels of data availability and security, the company continues to meet the needs of its growing, globally distributed customer base. Its partner-led delivery model and emphasis on localized support have been key to delivering long-term value across diverse market segments. Frost & Sullivan commends CTERA for setting a high standard in competitive strategy, execution, and market responsiveness. The company's vision, innovation pipeline, and customer-first culture are shaping the future of hybrid cloud storage and driving tangible results at scale. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The award recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & Sullivan For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact: E: [email protected] About CTERA CTERA is the global data management leader, enabling organizations of all sizes to efficiently and effectively manage, protect, store, and leverage their data across highly distributed environments. With a foundation built on military-grade security, limitless scale, and seamless integration, the CTERA Intelligent Data Platform empowers organizations to align their data management strategies to continuously deliver against today's business needs and tomorrow's vision.
Cision Canada
an hour ago
- Cision Canada
Readout - Prime Minister Carney participates in a virtual meeting in support of Ukraine
OTTAWA, ON, /CNW/ - Today, the Prime Minister, Mark Carney, participated in a virtual meeting of the Coalition of the Willing on support for Ukraine. The Coalition welcomed the leadership and initiative of President Trump and the United States and discussed ongoing efforts toward securing peace in Ukraine, in the context of upcoming ceasefire negotiations between the United States and Russia taking place in Anchorage, Alaska, on Friday, August 15, 2025. The leaders underscored their unity on shared principles, including that decisions on the future of Ukraine must be made by Ukrainians, that international borders cannot be changed by force, that diplomatic engagement must be reinforced by military and economic pressure on Russia to end its aggression, and the need for credible security guarantees to enable Ukraine to defend its territorial integrity and sovereignty. Prime Minister Carney affirmed Canada's steadfast support for Ukraine, including through $2 billion in new military support and the disbursement of a $2.3 billion loan through the G7 Extraordinary Revenue Acceleration Loans mechanism. The meeting was co-chaired by the Prime Minister of the United Kingdom, Sir Keir Starmer, the President of France, Emmanuel Macron, and the Chancellor of Germany, Friedrich Merz. The President of Ukraine, Volodymyr Zelenskyy, and the Vice President of the United States, JD Vance, also participated in the Coalition of the Willing meeting.
